Rallis Chris A's Form 4 filing
Fennec Pharmaceuticals Inc. (FENC) · filed May 19, 2023
- Accession no.
- 0001415889-23-008417
- Filed
- May 19, 2023
- Trade date
- May 19, 2023
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $12.9K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rallis Chris ACIK 0001185945 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 19, 2023 | Common Shares | SSaleDisposed | −833 | $7.36 | −$6,130.88 | 31,958 | Direct | |
| May 19, 2023 | Common Shares | SSaleDisposed | −925 | $7.36 | −$6,808 | 31,033 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.